Rani Therapeutics Holdings Inc (RANI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.87+1.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RANI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 129.2% |
| Our one-year growth estimate | diamond | 26.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 103.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RANI — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-05-15
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Glob…
Why it matters: Funding operations is vital for Rani's survival and growth. It affects future projects and trials.
Supportive ifThey announced they have enough cash and securities. This will fund operations until Q4 2027.
Worry ifThey announced a cash shortfall. They cannot fund operations past Q4 2027.
Why it matters: If sector revenue growth picks up, it could benefit Rani's performance.
Supportive ifSector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth continues to slow below 5%.
Why it matters: Earnings results will show how Rani is doing financially.
Worry ifEarnings report shows losses are much lower than before.
Less concerning ifEarnings report shows losses are getting bigger than now.
Why it matters: This notice affects Rani's stock listing and investor confidence. It could impact future funding and operations.
Worry ifRani gets word from Nasdaq that the delisting notice is resolved.
Less concerning ifRani does not meet Nasdaq's rules and may be delisted.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$232 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $954 loss on $10,000 · 9.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,780 loss on $10,000 · 77.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop below this level could signal funding issues for Rani's operations through 2027.
Worry ifCash and cash equivalents are below $40 million.
Less concerning ifCash and cash equivalents remain above $40 million.
Why it matters: Having enough cash is important for Rani's ongoing work and plans.
Supportive ifManagement says cash reserves will stay above $40 million in the next report.
Worry ifCash reserves drop below $30 million in the next quarterly report.
Why it matters: The new CFO's strategy can affect financial management and investor trust. This is key for future operations.
Watch forThe new CFO shares a plan that helps improve financial performance.
Also watch forThe CFO's plan causes more financial problems or bad news.
Why it matters: More data will show if RT-114's oral delivery works as well as expected. This could impact future trials.
Supportive ifPositive data reported by the end of 2026 from the Phase 1a expansion cohort of RT-114.
Worry ifNo new data or negative results reported by the end of 2026.
Why it matters: Starting the Phase 1b study is a key step in developing RT-114 for obesity treatment.
Supportive ifA Phase 1b study for RT-114 in patients with obesity has started.
Worry ifThe Phase 1b study announcement is delayed or canceled.
Why it matters: This partnership could grow Rani's obesity pipeline. It may also prove the RaniPill platform.
Supportive ifThe PegBio partnership has shown successful preclinical results. It has also made progress to clinical trials.
Worry ifThere are no updates or negative results from the PegBio partnership.